Pathstone Family Office’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
Other funds holding DGX
Pathstone Family Office's DGX Position: Q3 2023 in Review
Pathstone Family Office increased its Quest Diagnostics (DGX) stake by 2,401% in Q3 2023, buying an estimated $43M and bringing the position to 336,521 shares worth $41M. The position accounts for 0.31% of the portfolio, ranked #50.
Pathstone Family Office first reported a position in DGX in Q4 2018 and has held it in 19 quarters since. 794 funds tracked by Wall St. Rank hold DGX as of Q3 2023.
- Pathstone Family Office held 336,521 shares of Quest Diagnostics worth $41M as of Q3 2023.
- Pathstone Family Office bought 323,065 Quest Diagnostics shares in Q3 2023, an estimated $43M.
- Quest Diagnostics made up 0.31% of Pathstone Family Office's portfolio in Q3 2023, its #50 holding.
- Pathstone Family Office first reported a position in Quest Diagnostics in Q4 2018 and has held it in 19 quarters since.
- 794 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2023.
Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.